Drug Profile
Fluciclovine 18F - Emory University/GE Healthcare/Nihon Medi-Physics
Alternative Names: 18F-Ge-148; 18F fluciclovine; [18F]-FACBC; Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic-acid; Anti-1-amino-3-F-18-fluorocyclobutane-1-carboxylic-acid; Anti-1-amino-3-fluorine-18-fluorocyclobutane-1-carboxylic acid; Anti-18-F-FACBC; Anti-18F-FABC; Anti-3-18F-FACBC; Anti-F-18-fluorocyclobutane-carboxylic-acid; Axumin; Axumin-PET scan; FACBC; fluciclovine(18F); Fluciclovine-F-18; GE-148; Ge-148-18F; Ge-148-F-18; NMK-36; Trans-1-amino-3-18F-fluorocyclobutanecarboxylic-acidLatest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator Emory University
- Developer Blue Earth Diagnostics; Emory University; GE Healthcare; Memorial Sloan-Kettering Cancer Center; Nihon Medi-Physics; University of Arizona; University of Utah
- Class Amino acids; Carboxylic acids; Cyclobutanes; Imaging agents; Radiopharmaceutical diagnostics; Small molecules
- Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Prostate cancer
- Preregistration Glioma
- Phase III Brain metastases
- Phase II Bone metastases; Brain cancer
- Phase I Breast cancer
- No development reported Glioblastoma; Head and neck cancer; Lung cancer; Parathyroid cancer
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for phase-I development in Glioblastoma(Diagnosis) in USA (IV, Injection)
- 05 Jun 2023 Blue Earth Diagnostics completes the phase III REVELATE trial for Brain metastases (Diagnosis) in USA (IV) (NCT04410133)
- 02 Jun 2023 Efficacy data from the phase II PURSUE trial in Brain metastases presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)